Document:

Security Agreement

 Exhibit 10.3 
 SECURITY AGREEMENT 
 This SECURITY AGREEMENT (this “Agreement”) is entered
into as of March 23, 2012, by and between ORAGENICS, INC., a Florida corporation located at 3000 Bayport Drive, Suite 685 Tampa, Florida 33607 (“Borrower”), and KOSKI FAMILY LIMITED PARTNERSHIP, a Texas limited partnership
having a mailing address of 3525 Turtle Creek Boulevard, Unit 19-B, Dallas, Texas 75219 (“Lender”) 

Background 
  

	C.	On the date of this Agreement, Lender loaned Borrower Two Million Five Hundred Thousand and No/100 Dollars ($2,500,000.00) (the “Loan”), pursuant to
the terms of a Senior Secured Convertible Promissory Note of even date herewith executed by Borrower in favor of Lender in the principal amount of Two Million Five Hundred Thousand and No/100 Dollars ($2,500,000.00) (the “Promissory
Note”). 

  

	D.	As a material inducement for Lender to make the Loan to Borrower pursuant to the terms of the Promissory Note, Borrower has agreed to provide collateral security for
the performance of its obligations and liabilities under the Promissory Note, pursuant to the terms and conditions of this Agreement. 

 Terms and Conditions 
 For the reasons described above, in consideration of the mutual
promises and covenants set forth in this Agreement, and for other good and valuable consideration, the receipt and adequacy of which are hereby acknowledged by the parties, Borrower and Lender hereby agree as follows: 

Definitions. The following capitalized terms used in this Agreement shall have the meanings assigned to them in this Section 0, and shall include the
plural as well as the singular number: 
 “Collateral” means the assets of Borrower listed on Exhibit A, whether now
owned or hereafter acquired by Borrower, and all products thereof, and all replacements, replenishments, additions, accessions, and substitutions thereof and the proceeds thereof including, without limitation, the following: 

all patents, patent disclosures, trademarks, service marks, trade dress, logos, trade names, copyrights, art and mask works, manuals and
information, and all registrations, applications, reissues, continuations, continuations in part or extensions thereof, and all associated goodwill for each of the foregoing, and all computer software, computer programs, computer data bases and
related documentation and materials, data, documentation, trade secrets, confidential business information (including ideas, formulas, compositions, inventions, know how, business processes and techniques, research and development

 
information, drawings, designs, plans, proposals and technical data, financial, marketing and business data, customer and supplier data, pricing and cost information) and other intellectual
property rights (in whatever form or medium), whether owned or licensed by the Borrower, including the Intellectual Property (as defined in Section 5.1(a) below). 
 without limiting the generality of the foregoing, to the extent related to all or any part of the other Collateral, all books, correspondence, credit files, records, invoices, tapes, cards, computer runs
and other papers and documents in the possession or under the control of Borrower or any computer bureau or service company from time to time acting for Borrower. 
 “Event of Default” means the occurrence of any one or more of the following events: 
 any event of default under the Promissory Note; 
 any default by Borrower under
this Agreement and if such default is capable of being remedied, such default remains unremedied for thirty (30) days, including the breach or material inaccuracy of any representation, warranty or covenant of Borrower under this Agreement;

 the inability of Borrower, or the admission by Borrower of its inability, to pay its debts as they mature, or the insolvency
of Borrower; 
 the filing against Borrower of an involuntary petition or other pleading seeking the entry of a decree or order
for relief under the United States Bankruptcy Code or any similar federal or state insolvency or other similar law ordering: (i) the liquidation of Borrower, (ii) a reorganization of Borrower or the business and affairs of Borrower, or
(iii) the appointment of a receiver, liquidator, assignee, custodian, trustee or similar official for Borrower or the property of Borrower, and the failure to have such petition or other pleading denied or dismissed within thirty (30) days
from the date of filing; 
 (i) the commencement by Borrower of a voluntary case under the United States Bankruptcy Code or any
similar federal or state insolvency or other similar law, (ii) the consent by Borrower to the appointment or taking possession by a receiver, liquidator, assignee, trustee, custodian or similar official for Borrower or any of the property of
Borrower, (iii) the making by Borrower of an assignment for the benefit of creditors, or (iv) the failure by Borrower generally to pay its debts as they become due; or 

the making of any levy, seizure or attachment of or on the Collateral by any third party. 

 “Liability” or “Liabilities” means all monetary obligations and
liabilities of Borrower to Lender under the Promissory Note, whether now existing or hereafter incurred, matured or unmatured, direct or indirect, absolute or contingent, now due or hereafter to become due, as well as all costs and reasonable
expenses of collection, including reasonable attorneys’ fees, paralegals’ fees and expenses for any primary, appellate, bankruptcy and post-judgment proceedings, incurred by Lender in connection with the enforcement of the Promissory Note
or this Agreement. 
 Grant of Security Interest. To secure the full and punctual payment of all Liabilities, Borrower hereby grants to Lender a
continuing security interest in the Collateral, free and clear of any and all prior liens, encumbrances or charges whatsoever. 
 Perfection of
Security Interest. To perfect the security interest granted above, Borrower authorizes Lender to file financing statements in forms that are satisfactory to Lender (including amendments thereto and continuation statements thereof and filings with
the United States Patent and Trademark Office), describing the Collateral and containing such legends as Lender deems necessary or appropriate to protect Lender’s interest in the Collateral. Borrower agrees to pay all taxes, fees and costs
(including reasonable attorneys’ fees) paid or incurred by Lender in connection with the preparation, filing or recordation of such documents and instruments. Borrower shall not file any amendments, correction statement or termination
statements concerning the Collateral without the prior written consent of Lender. Borrower shall, from time to time, at the request of Lender, execute such other documents and perform such other acts reasonably necessary or appropriate to establish
and maintain a valid and perfected security interest in the Collateral, free of all other liens and claims whatsoever. Borrower hereby appoints Lender as its attorney-in-fact (without requiring it to act as such) to perform all acts that Lender
deems necessary or appropriate to perfect and continue its security interest in the Collateral. Borrower hereby acknowledges that this power of attorney is coupled with an interest and is irrevocable until all Liabilities have been fully paid.

 Patents, Trademarks, etc. Borrower shall notify Lender immediately upon the occurrence of each of the following
(i) Borrower’s acquisition after the date of this Agreement of any material Intellectual Property and (ii) a Responsible Officer of Borrower obtaining knowledge, or reason to know, that any application or registration relating to any
Intellectual Property owned by or licensed to Borrower is reasonably likely to become abandoned or dedicated, or of any material adverse determination or development (including, without limitation, the institution of, or any such determination or
development in, any proceeding in the United States Copyright Office, the United States Patent and Trademark Office or any court) regarding Borrower’s ownership of any material Intellectual Property, its right to register the same, or to keep
and maintain the same. Borrower will, contemporaneously herewith, execute and deliver to Lender the Patent Security Agreement, Trademark Security Agreement and Copyright Security Agreement in the forms of Exhibit B, Exhibit C and Exhibit D hereto,
as necessary, and shall execute and deliver to Lender any other document required to acknowledge or register or perfect Lender’s interest in any part of the Intellectual Property. Notwithstanding anything to the contrary contained in this
Agreement, Lender shall only require perfection of its security interests in, or other registration with respect to, any patent, trademark or copyright registered, or eligible to be registered, with a country other than the

 
United States or any political subdivision thereof, to the extent that Lender determines, in its sole discretion, that such patent, trademark or copyright, and the registration thereof in such
other country or political subdivision thereof, is material to Borrower’s business. 
 Representations and Warranties. Borrower represents
and warrants to Lender as follows: 
 Representations and Warranties Regarding Intellectual Property. 

Schedule 5.1(a) attached to this Agreement contains a true, correct and complete list of patents, trademarks, service marks, trade
names and copyrights owned by Borrower which are subject to the security interest created hereby, including any applications therefor (collectively, the “Intellectual Property”) and including, where applicable, the patent,
trademark, service mark or copyright number (or application number), issue date and title. 
 Borrower is the sole and exclusive
owner of all right, title and interest in and to the Intellectual Property and has not granted, nor does there exist by implication or operation of law, any license or other right in respect thereof which does or which will, subsequent to the date
of this Agreement, permit or enable anyone other than Borrower to use any of the Intellectual Property. 
 No individual or
entity has any rights to utilize any Intellectual Property or sell any products or services which utilize or incorporate, or which were developed utilizing or incorporating, any Intellectual Property. 

There is no notice or pending or threatened claim against Borrower (and there has not been any such notice or claim) asserting
(i) that any of the Intellectual Property infringes or violates the rights of third parties; (ii) that any of the Intellectual Property is invalid; (iii) that the present or past conduct of Borrower’s business infringes or
violates any rights of others with respect to any of the Intellectual Property; (iv) that any individual or entity has any rights to utilize any of the Intellectual Property or sell any products or devices which utilize or incorporate, or which
were developed utilizing or incorporating, any Intellectual Property; or (v) which could, if adversely determined against Borrower, adversely affect Borrower’s ability to utilize any of the Intellectual Property, and no basis for any such
claim exists. 
 Borrower has not given any notice to any third parties asserting infringement by such third parties upon any of
the Intellectual Property. 
 General Representations and Warranties. 

Borrower is a corporation duly organized, legally existing and in good standing under the laws of the State of Florida. 

 Borrower is the owner of the Collateral free from any security interest, encumbrance, or
lien, and will defend the Collateral against all claims and demands of all persons at any time claiming the same. 
 No financing
statement covering any Collateral or any proceeds thereof is on file in any public office, except for that which may be on file to perfect the security interest of Lender. 
 Borrower is not in default with respect to any of its existing indebtedness, and the making and performance of this Agreement will not violate any laws or result in a default under any contract,
agreement, or instrument to which Borrower is a party or by which its property is bound, or result in the creation or imposition of any security interest in, or lien or encumbrance upon, any of its assets, except in favor of Lender. 

Borrower has the power and authority to enter into and perform this Agreement and to incur the obligations herein provided for, and has
taken all action necessary to authorize the execution, delivery, and performance of this Agreement. 
 This Agreement, when
delivered, will be valid, binding and enforceable against Borrower in accordance with its terms. 
 No representation, warranty
or statement of Borrower hereunder omits to state any material fact necessary to make each representation or warranty or statement in this Agreement by Borrower accurate and not misleading in any material respect. 

Affirmative Covenants. Borrower covenants that, until such time as all of the Liabilities have been fully satisfied paid, it shall

 take all actions necessary to prosecute any pending applications with respect to the Intellectual Property; 

take all actions necessary to protect its rights with respect to the Intellectual Property, including bringing appropriate actions to
prevent infringement of such rights; 
 promptly notify Lender of any actual or threatened infringement of Borrower’s rights
with respect to the Intellectual Property; 
 promptly notify Lender of the occurrence of any Event of Default or any event or
condition which, with the giving of notice and/or the lapse of time, could constitute an Event of Default; 

 pay or cause to be paid when due, all taxes, assessments, and charges or levies imposed upon
the Collateral; 
 notify Lender thirty (30) days in advance of any change in the location of its business, or of the
establishment of any new, or the discontinuance of any existing, place of business; 
 continuously maintain, preserve, and keep
in full force and effect, its corporate existence, good standing, and its right and privilege to conduct business in Florida; 

permit Lender or its representatives at any time to inspect as frequently as reasonably requested the Collateral, wherever located, and it
shall fully and timely assist Lender in regard to such inspections to the extent requested by Lender; and 
 maintain insurance,
at full replacement cost, on the Collateral. 
 Remedies Upon Default. Upon the occurrence of an Event of Default, Lender may declare all
Liabilities to be immediately due and payable and may, at its option and without notice or demand on Borrower and in addition to all the rights and remedies that accrue to a secured party under the Uniform Commercial Code as in effect in under
applicable law or that are otherwise available to Lender under applicable law, do any one or more of the following: (a) foreclose or otherwise endorse Lender’s interest in the Collateral in any manner permitted by law, or provided for in
this Agreement; or (b) sell, lease, license or otherwise dispose of any Collateral at one or more public or private sales, whether or not such collateral is present at the place of sale, for cash or credit or future delivery, on such terms and
in such manner as Lender may determine. Borrower expressly waives any constitutional or other right to a judicial hearing prior to the time Lender takes possession or disposes of the Collateral upon default as provided in this Section 8.

 General Provisions. 

Choice of Law; Venue. The laws of the State of Florida, excluding its choice of law provisions if such laws would result in the
application of laws other than the laws of the State of Florida, shall govern any disputes with respect to this Agreement, the validity of this Agreement, the construction of its terms, and the interpretation of the rights and duties of Borrower and
Lender hereunder. The forum selected for any proceeding or suit related to a dispute between Borrower and Lender related to this Agreement shall be in a federal or state court of competent jurisdiction located in Hillsborough County, Florida.
Borrower and Lender each consent to said courts’ personal jurisdiction over it and waive any defense, whether asserted by motion or pleading, that Hillsborough County, Florida is an improper or inconvenient venue. 

 Notice. Any notice, demand or other communication to a party that is permitted or required
hereunder shall be given in writing, and shall be deemed to have been duly delivered (i) when delivered by personal delivery, (ii) three (3) days after being deposited with the United States Postal Service for mailing by first class
mail, postage prepaid, certified mail, with return receipt requested (regardless of whether the return receipt is subsequently received), or (iii) one business day after being deposited with a nationally recognized courier service for overnight
delivery; and in each case addressed by the sender to the recipient at the address first listed above, or to such other address as party may notify the other party in writing in conformity with the provisions of this Section. 

Further Action. Each party agrees to take all further action, and to execute, acknowledge, and deliver any other documents, which may be
reasonably necessary, appropriate, or desirable to carry out the provisions of this Agreement. 
 No Agency. Nothing contained in
this Agreement shall be deemed to create any association, partnership or joint venture between the parties. 
 Amendment. The
Agreement may be amended only by a written instrument signed by both parties. 
 Assignment. Lender may assign its rights under
this Agreement in connection with the assignment of the Promissory Note. 
 No Waiver. No waiver of any provision of this
Agreement, and no consent to any departure by a party from the terms and conditions of this Agreement, shall be effective unless such waiver or consent is given in writing by the party against whom the waiver is being sought (in which the case the
waiver or consent shall be effective only in the specific instance, and only for the specific purpose, for which it was given). No failure or delay by a party in exercising any right or remedy, or requiring the satisfaction of any condition under
this Agreement, and no course of dealing between the parties, shall operate as a waiver or estoppel of any right or remedy of such party hereunder, or limit or prevent the subsequent enforcement of any provision of this Agreement by such party.

 Integration. This Agreement, together with the Promissory Note (collectively, the “Loan Documents”), constitutes the
final agreement among the parties. They are the complete and exclusive expression of the parties’ agreement on the matters contained in the Loan Documents. All prior and contemporaneous negotiations and agreements between the parties on the
matters contained in the Loan Documents are expressly merged into and superseded by the Loan Documents. The provisions of the Loan 

 
Documents may not be explained, supplemented, or qualified through evidence of trade usage or a prior course of dealings. In entering into the Loan Documents, no party has relied upon any
statement, representation, warranty or agreement of the other party except for those expressly contained in the Loan Documents. There are no conditions precedent to the effectiveness of the Loan Documents other than those expressly stated in the
Loan Documents. 
 Severability. If any provision of this Agreement is determined to be invalid, illegal or unenforceable, the
remaining provisions of this Agreement shall remain in full force, if the essential terms and conditions and conditions of this Agreement for each party remain valid, binding and enforceable. 

Successors and Assigns. This Agreement shall be binding upon, and shall inure to the benefit of, the parties and their respective
successors and permitted assignees. 
 Counterparts. The parties may execute this Agreement in multiple counterparts, each of
which constitutes an original, and all of which, collectively, constitute only one agreement. The signatures of the parties need not appear on the same counterpart, and delivery of an executed counterpart signature page by facsimile or other form of
electronic transmission shall be as effective as executing and delivering this Agreement in the presence of the other parties to this Agreement. This Agreement shall be binding when each party to this Agreement has delivered an executed counterpart
signature page to each other party. 
 Number and Gender. Except where the context requires otherwise, any reference in this
Agreement to the singular includes the plural, and any reference in this Agreement to the masculine gender includes the feminine and neuter gender. 
 Descriptive Headings. The titles and captions preceding the text of the sections of this Agreement are inserted solely for convenient reference and neither constitute a part of this Agreement nor affect
its meaning, interpretation, or effect. 
 Authority. Each individual executing this Agreement on behalf of an entity represents
and warrants that he or she is duly authorized to execute and deliver this Agreement on behalf of the entity and that this Agreement is binding upon the entity. 
 Release of Collateral. Secured Party covenants and agrees that provided that no Event of Default exists and is continuing that it shall release from the lien and operation of this Agreement, as well as
any financing statement or other filing made to perfect Secured Party’s security interest in and to the Collateral, all portions of the Collateral which have been approved by the Borrower’s Board of Directors for sale or license.

 [Continued on next page.] 

 Computation of Time. Whenever the last day for the exercise of any privilege or the
discharge of any duty under this Agreement shall fall upon Saturday, Sunday or any public or legal holiday, whether federal or of the State of Florida, the party having such privilege or duty shall have until 5:00 p.m. on the next succeeding regular
business day to exercise such privilege or to discharge such duty. 

 IN WITNESS WHEREOF, the parties have executed this SECURITY AGREEMENT on the date first indicated above.

  

			
	“Borrower”
	
	 ORAGENICS, INC.,
 a
Florida corporation

		
	By:	 	 /s/ John Bonfiglio

	Name:	 	John Bonfiglio
	Its:	 	President and Chief Executive Officer
	
	“Lender”
	
	 KOSKI FAMILY LIMITED PARTNERSHIP,
 a Texas limited partnership

		
	By:	 	 /s/ Christine Koski

	Name:	 	Christine Koski
	Its:	 	Managing General Partner

 EXHIBIT A 
 TO SECURITY AGREEMENT 
 Company Technologies Securing Loan 

The Security for the Loan is limited to the following Company technologies: 

 

							
	 Product/Candidate
	  	 Description
	  	 Application
	  	 Status

	SMaRT Replacement Therapy	  	Genetically modified strain of S. mutans that does not produce lactic acid	  	Tooth decay	  	Second Phase 1 clinical trial
				
	ProBiora32	  	Blend of three beneficial oral probiotic bacteria	  	Oral health, teeth whitening, breath freshening (humans, companion pets)	  	Commercial (GRAS)
				
	LPT3-04	  	Naturally occurring compound	  	Weight loss product	  	Under development
				
	DPOLT	  	Organic chemistry platform	  	Enables scalable production of lantibiotics	  	Synthetic production under development
				
	MU1140-S	  	Member of lantibiotic class of antibiotics	  	Healthcare-associated infections	  	Preclinical testing

  

	2	The Security includes all ProBiora3 branded Company products, as well as any trademarks relating to such branded products. 

For clarification purposes the following are specifically not part of the Security for the Loan: 

 

	 	•	 	 Biomarker Discovery Platform (PCMAT) a discovery platform is based on our Proteomics-based Change Mediated Antigen Technology, or PCMAT;

  

	 	•	 	 PostBiotic (MANR) technologies; and 

  

	 	•	 	 Company Accounts Receivable. 

 Exhibit B 
 Patent Security Agreement 
 PATENT SECURITY AGREEMENT 

THIS PATENT SECURITY AGREEMENT (as amended, restated, or supplemented at any time or from time to time, this “Agreement”), dated
as of March 23, 2012, between Oragenics, Inc., a Florida corporation (“Grantor”), in favor of Koski Family Limited Partnership, a Texas limited partnership (the “Lender”). 

W I T N E S S E T H : 

WHEREAS, Grantor is justly indebted to Lender in the principal amount of $2,500,000.00, as evidenced by Grantor’s Senior Secured Convertible
Promissory Note (as modified, supplemented, amended, restated, or as the indebtedness evidenced thereby may be increased, decreased, adjusted, split into more than one indebtedness, consolidated with other indebtedness, adjusted, rearranged or
recharacterized at any time or from time to time, the “Note”) in said principal sum dated March 23, 2012 and payable to the order of Lender, which Note is secured by, inter alios, that certain Security Agreement (as
amended, supplemented, amended and restated or otherwise modified from time to time, the “Security Agreement”) dated March 23, 2012, from Grantor in favor of Lender, which grants to Lender a security interest in all general
intangibles of Grantor; 
 WHEREAS, as required by Lender, the Grantor is executing this Agreement and to further evidence and to grant
to the Lender a continuing security interest in all of the Patent Collateral (as defined below) to secure the indebtedness evidenced by the Note; and 
 WHEREAS, the Grantor has duly authorized the execution, delivery and performance of this Agreement; 
 NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Grantor agrees, for the benefit of Lender, as follows: 

SECTION 1. Definitions. Unless otherwise defined herein or the context otherwise requires, terms used in this Agreement, including its preamble
and recitals, have the meanings provided (or incorporated by reference) in the Security Agreement. 
 SECTION 2. Grant of Security
Interest. For good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, to secure the indebtedness evidenced by the Note, the Grantor does hereby mortgage, pledge and hypothecate to the Lender, and grant to
the Lender a security interest in all of the following property (the “Patent Collateral”), whether now owned or hereafter acquired or existing by it: 
 (a) all letters patent and applications for letters patent throughout the world, including all patent applications in preparation for filing anywhere in the world and including each patent and patent
application referred to in Item A of Schedule I attached hereto; 
 (b) all reissues, divisions, continuations,
continuations-in-part, extensions, renewals and reexaminations of any of the items described in clause (a); 
 (c) all patent
licenses, including each patent license referred to in Item B of Schedule I attached hereto; and 
 (d) all
proceeds of, and rights associated with, the foregoing (including license royalties and proceeds of infringement suits), the right to sue third parties for past, present or future infringements of any patent or patent application, including any
patent or patent application referred to in Item A of Schedule I attached hereto, and for breach or enforcement of any patent license, including any patent license referred to in Item B of Schedule I attached hereto, and all rights corresponding
thereto throughout the world. 

 SECTION 3. Security Agreement. This Agreement has been executed and delivered by the Grantor for the
purpose of registering the security interest of the Lender in the Patent Collateral with the United States Patent and Trademark Office and corresponding offices in other countries of the world. The security interest granted hereby has been granted
as a supplement to, and not in limitation of, the security interest granted to the Lender under the Security Agreement. The Security Agreement (and all rights and remedies of the Lender thereunder) shall remain in full force and effect in accordance
with its terms subject to Section 4 hereof. 
 SECTION 4. Release of Security Interest. Upon the payment in full of the indebtedness
evidenced by the Note, the Lender shall promptly upon the Grantor’s request and contemporaneously with any refinancing of the indebtedness evidenced by the Note, at the Grantor’s expense, execute and deliver to the Grantor all instruments
and other documents as may be necessary or proper to release the lien on and security interest in the Patent Collateral which has been granted hereunder. 
 SECTION 5. Acknowledgment. The Grantor does hereby further acknowledge and affirm that the rights and remedies of the Lender with respect to the security interest in the Patent Collateral granted
hereby are more fully set forth in the Security Agreement, the terms and provisions of which (including the remedies provided for therein) are incorporated by reference herein as if fully set forth herein. 

SECTION 6. Loan Document, etc. This Agreement is a Loan Document executed pursuant to the Note and shall (unless otherwise expressly indicated
herein) be construed, administered and applied in accordance with the terms and provisions of the Note. 
 SECTION 7. Counterparts. This
Agreement may be executed by the parties hereto in several counterparts, each of which shall be deemed to be an original (whether such counterpart is originally executed or an electronic copy of an original) and all of which shall constitute
together but one and the same agreement. 
 [Remainder of Page Intentionally Blank] 

 IN WITNESS WHEREOF, the Grantor has caused this Agreement to be duly executed and delivered by the
below named duly authorized officer as of the day and year first above written. 
  

					
	ORAGENICS, INC.,
	a Florida corporation
			
		 	By:	 	  

		 	Name:	 	  

		 	Title:	 	  

 SCHEDULE I 
 TO PATENT SECURITY AGREEMENT 
 Item A. Patents 

Issued Patents 
  

									
	 *Country
	  	 Patent No.
	  	 Issue Date
	  	 Inventor(s)
	  	 Title

	  	  	 	  	 	  	 	  	 

 Pending Patent Applications 

 

									
	 *Country
	  	 Application No.
	  	 Filing Date
	  	 Inventor(s)
	  	 Title

	  	  	 	  	 	  	 	  	 

 Patent Applications in Preparation 

 

									
	 *Country
	  	 Docket No.
	  	 Expected
Filing Date
	  	 Inventor(s)
	  	 Title

	  	  	 	  	 	  	 	  	 

 Item B. Patent Licenses 

 

											
	 *Country or Territory
	  	 Licensor
	  	 Licensee
	  	 Effective
Date
	  	 Expiration
Date
	  	 Subject
Matter

	  	  	 	  	 	  	 	  	 	  	 

  

	*	List items related to the United States first for ease of recordation. List items related to other countries next, grouped by country and in alphabetical order by
country name. 

 Exhibit C 
 Trademark Security Agreement 
 TRADEMARK SECURITY AGREEMENT

 THIS TRADEMARK SECURITY AGREEMENT (as amended, restated, or supplemented at any time or from time to time, this
“Agreement”), dated as of March 23, 2012, between Oragenics, Inc., a Florida corporation (“Grantor”), in favor of Koski Family Limited Partnership, a Texas limited partnership (the “Lender”).

 W I T N E S S E T H : 
 WHEREAS, Grantor is justly indebted to Lender in the principal amount of $2,500,000.00, as evidenced by Grantor’s Senior Secured Convertible Promissory Note (as modified, supplemented,
amended, restated, or as the indebtedness evidenced thereby may be increased, decreased, adjusted, split into more than one indebtedness, consolidated with other indebtedness, adjusted, rearranged or recharacterized at any time or from time to time,
the “Note”) in said principal sum dated March 23, 2012 and payable to the order of Lender, which Note is secured by, inter alios, that certain Security Agreement (as amended, supplemented, amended and restated or
otherwise modified from time to time, the “Security Agreement”) dated March 23, 2012, from Grantor in favor of Lender, which grants to Lender a security interest in all general intangibles of Grantor; 

WHEREAS, as required by Lender, the Grantor is executing this Agreement and to further evidence and to grant to the Lender a continuing security
interest in all of the Trademark Collateral (as defined below) to secure the indebtedness evidenced by the Note; and 
 WHEREAS, the
Grantor has duly authorized the execution, delivery and performance of this Agreement; 
 NOW, THEREFORE, for good and valuable
consideration, the receipt and sufficiency of which are hereby acknowledged, the Grantor agrees, for the benefit of Lender, as follows: 

SECTION 1. Definitions. Unless otherwise defined herein or the context otherwise requires, terms used in this Agreement, including its preamble
and recitals, have the meanings provided (or incorporated by reference) in the Security Agreement. 
 SECTION 2. Section 3. Grant of
Security Interest. For good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, to secure all of the Obligations, the Debtor does hereby mortgage, pledge and hypothecate to the Secured Party, and grant to
the Secured Party a security interest in, for its benefit and the benefit of the Secured Party, all of the following property (the “Trademark Collateral”), whether now owned or hereafter acquired or existing by it: 

(a) all trademarks, trade names, corporate names, company names, business names, fictitious business names, trade styles, service marks,
certification marks, collective marks, logos, other source of business identifiers, prints and labels on which any of the foregoing have appeared or appear, designs and general intangibles of a like nature (all of the foregoing items in this
clause (a) being collectively called a “Trademark”), now existing anywhere in the world or hereafter adopted or acquired, whether currently in use or not, all registrations and recordings thereof and all applications in
connection therewith, whether pending or in preparation for filing, including registrations, recordings and applications in the United States Patent and Trademark Office or in any office or agency of the United States of America or any State thereof
or any foreign country, including those referred to in Item A of Schedule I attached hereto; 
 (b) all Trademark
licenses, including each Trademark license referred to in Item B of Schedule I attached hereto; 
 (c) all
reissues, extensions or renewals of any of the items described in clause (a) and (b); 
 (d) all of the
goodwill of the business connected with the use of, and symbolized by the items described in, clauses (a) and (b); and 

 (e) all proceeds of, and rights associated with, the foregoing, including any claim by the
Debtor against third parties for past, present or future infringement or dilution of any Trademark, Trademark registration or Trademark license, including any Trademark, Trademark registration or Trademark license referred to in Item A and
Item B of Schedule I attached hereto, or for any injury to the goodwill associated with the use of any such Trademark or for breach or enforcement of any Trademark license. 
 Section 4. Security Agreement. This Agreement has been executed and delivered by the Debtor for the purpose of registering the security interest of the Secured Party in the Trademark
Collateral with the United States Patent and Trademark Office and corresponding offices in other countries of the world. The security interest granted hereby has been granted as a supplement to, and not in limitation of, the security interest
granted to the Secured Party under the Security Agreement. The Security Agreement (and all rights and remedies of the Secured Party) shall remain in full force and effect in accordance with its terms subject to Section 5 hereof. 

SECTION 4. Release of Security Interest. Upon the payment in full of the indebtedness evidenced by the Note, the Lender shall promptly upon the
Grantor’s request and contemporaneously with any refinancing of the indebtedness evidenced by the Note, at the Grantor’s expense, execute and deliver to the Grantor all instruments and other documents as may be necessary or proper to
release the lien on and security interest in the Trademark Collateral which has been granted hereunder. 
 SECTION 5. Acknowledgment. The
Grantor does hereby further acknowledge and affirm that the rights and remedies of the Lender with respect to the security interest in the Trademark Collateral granted hereby are more fully set forth in the Security Agreement, the terms and
provisions of which (including the remedies provided for therein) are incorporated by reference herein as if fully set forth herein. 
 SECTION
6. Loan Document, etc. This Agreement is a Loan Document executed pursuant to the Note and shall (unless otherwise expressly indicated herein) be construed, administered and applied in accordance with the terms and provisions of the Note.

 SECTION 7. Counterparts. This Agreement may be executed by the parties hereto in several counterparts, each of which shall be deemed
to be an original (whether such counterpart is originally executed or an electronic copy of an original) and all of which shall constitute together but one and the same agreement. 

[Remainder of Page Intentionally Blank] 

 IN WITNESS WHEREOF, the Grantor has caused this Agreement to be duly executed and
delivered by the below named duly authorized officer as of the day and year first above written. 
  

					
	ORAGENICS, INC.,
	a Florida corporation
			
		 	By:	 	  

		 	Name:	 	  

		 	Title:	 	  

 SCHEDULE I 
 to Trademark Security Agreement 
 Item A. Trademarks 

Registered Trademarks 
  

							
	 *Country
	  	 Trademark
	  	 Registration No.
	  	 Registration Date

	  	  	  	  	  	  	  

 Pending Trademark Applications 

 

							
	 *Country
	  	 Trademark
	  	 Serial No.
	  	 Filing Date

	  	  	  	  	  	  	  

 Trademark Applications in Preparation 

 

									
	 *Country
	  	 Trademark
	  	 Docket No.
	  	 Expected
Filing Date
	  	 Products/
Services

	 	  	 	  	 	  	 	  	 

 Item B. Trademark Licenses 

 

											
	 *Country or Territory
	  	 Trademark
	  	 Licensor
	  	 Licensee
	  	 Effective
Date
	  	 Expiration
Date

	 	  	 	  	 	  	 	  	 	  	 

  

	*	List items related to the United States first for ease of recordation. List items related to other countries next, grouped by country and in alphabetical order by
country name. 

 Exhibit D 
 COPYRIGHT SECURITY AGREEMENT 
 THIS COPYRIGHT SECURITY AGREEMENT (as amended,
restated, or supplemented at any time or from time to time, this “Agreement”), dated as of March 23, 2012, between Oragenics, Inc., a Florida corporation (“Grantor”), in favor of Koski Family Limited
Partnership, a Texas limited partnership (the “Lender”). 
 W I T N E S S E T H : 

WHEREAS, Grantor is justly indebted to Lender in the principal amount of $2,500,000.00, as evidenced by Grantor’s Senior Secured Convertible
Promissory Note (as modified, supplemented, amended, restated, or as the indebtedness evidenced thereby may be increased, decreased, adjusted, split into more than one indebtedness, consolidated with other indebtedness, adjusted, rearranged or
recharacterized at any time or from time to time, the “Note”) in said principal sum dated March 23, 2012 and payable to the order of Lender, which Note is secured by, inter alios, that certain Security Agreement (as
amended, supplemented, amended and restated or otherwise modified from time to time, the “Security Agreement”) dated March 23, 2012, from Grantor in favor of Lender, which grants to Lender a security interest in all general
intangibles of Grantor; 
 WHEREAS, as required by Lender, the Grantor is executing this Agreement and to further evidence and to grant
to the Lender a continuing security interest in all of the Copyright Collateral (as defined below) to secure the indebtedness evidenced by the Note; and 
 WHEREAS, the Grantor has duly authorized the execution, delivery and performance of this Agreement; 
 NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Grantor agrees, for the benefit of Lender, as follows: 

SECTION 1. Definitions. Unless otherwise defined herein or the context otherwise requires, terms used in this Agreement, including its preamble
and recitals, have the meanings provided (or incorporated by reference) in the Security Agreement. 
 SECTION 2. Grant of Security
Interest. For good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, to secure all of the Obligations, the Grantor does hereby mortgage, pledge and hypothecate to the Lender, and grant to the Lender a
security interest in all of the following property (the “Copyright Collateral”), whether now owned or hereafter acquired or existing by it, being all copyrights (including all copyrights for semi-conductor chip product mask works)
of the Grantor, whether statutory or common law, registered or unregistered, now or hereafter in force throughout the world including all of the Grantor’s right, title and interest in and to all copyrights registered in the United States
Copyright Office or anywhere else in the world and also including the copyrights referred to in Item A of Schedule I attached hereto, and all applications for registration thereof, whether pending or in preparation, all copyright licenses, including
each copyright license referred to in Item B of Schedule I attached hereto, the right to sue for past, present and future infringements of any thereof, all rights corresponding thereto throughout the world, all extensions and renewals of any thereof
and all proceeds of the foregoing, including licenses, royalties, income, payments, claims, damages and proceeds of suit. 
 SECTION 3.
Security Agreement. This Agreement has been executed and delivered by the Grantor for the purpose of registering the security interest of the Lender in the Copyright Collateral with the United States Copyright Office and corresponding offices
in other countries of the world. The security interest granted hereby has been granted as a supplement to, and not in limitation of, the security interest granted to the Lender for its benefit and the benefit of each Lender under the Security
Agreement. The Security Agreement (and all rights and remedies of the Lender thereunder) shall remain in full force and effect in accordance with its terms subject to Section 4. 

 SECTION 4. Release of Security Interest. Upon the payment in full of the indebtedness evidenced by
the Note, the Lender shall promptly upon the Grantor’s request and contemporaneously with any refinancing of the indebtedness evidenced by the Note, at the Grantor’s expense, execute and deliver to the Grantor all instruments and other
documents as may be necessary or proper to release the lien on and security interest in the Patent Collateral which has been granted hereunder. 

SECTION 5. Acknowledgment. The Grantor does hereby further acknowledge and affirm that the rights and remedies of the Lender with respect to the
security interest in the Copyright Collateral granted hereby are more fully set forth in the Security Agreement, the terms and provisions of which (including the remedies provided for therein) are incorporated by reference herein as if fully set
forth herein. 
 SECTION 6. Loan Document, etc. This Agreement is a Loan Document executed pursuant to the Credit Agreement and shall
(unless otherwise expressly indicated herein) be construed, administered and applied in accordance with the terms and provisions of the Credit Agreement. 
 SECTION 7. Counterparts. This Agreement may be executed by the parties hereto in several counterparts, each of which shall be deemed to be an original (whether such counterpart is originally
executed or an electronic copy of an original) and all of which shall constitute together but one and the same agreement. 

[Remainder of Page Intentionally Blank] 

 IN WITNESS WHEREOF, the Grantor has caused this Agreement to be duly executed and delivered by the
below named duly authorized officer as of the day and year first above written. 
  

					
	ORAGENICS, INC.,
	a Florida corporation
			
		 	By:	 	  

		 	Name:	 	  

		 	Title:	 	  

 SCHEDULE I 
 TO COPYRIGHT SECURITY AGREEMENT 
 Item A. Copyrights 

Registered Copyrights 
  

							
	 *Country
	  	 Trademark
	  	 Copyright No.
	  	 Registration Date

	 	  	 	  	 	  	 

 Pending Copyright Applications 

 

							
	 Country
	  	 Copyright
	  	 Application No.
	  	 Filing Date

	 	  	 	  	 	  	 

 Item B: Copyright Licenses 

 

											
	 Country or Territory
	  	 Copyright
	  	 Licensor
	  	 Licensee
	  	 Effective
Date
	  	 Expiration
Date

	 	  	 	  	 	  	 	  	 	  	 

  

	*	List items related to the United States first for ease of recordation. List items related to other countries next, grouped by country and in alphabetical order by
country name. 

 Schedule 5.1(a) 
 I. Patents 
 Item A. Patents Issued  

 

									
	 Issued Patents

					
	 *Country
	  	 Patent No.
	 	 Filing Date
	  	 Inventor(s)
	  	 Title

	United States	  	7,931,892	 	06/30/06	  	Hillman	  	ProBiora3 Composition and methods for maintenance of oral health
					
	United States	  	7,521,529	 	08/11/06	  	Hillman, et al	  	DPOLT
					
	Australia	  	20044266615	 	08/10/04	  	Hillman	  	ProBiora3
		  	2005302173	 	11/02/05	  	Hillman, et al	  	LPT3-04
					
	Belgium	  	915389	 	06/08/11	  	Hillman, et al	  	DPOLT
					
	Canada	  	2535764	 	08/10/04	  	Hillman	  	ProBiora3
					
	China	  	ZL2005580045110.9	 	11/2/05	  	Hillman, et al	  	LPT3-04
					
	Denmark	  	1915389	 	06/08/11	  	Hillman, et al	  	DPOLT
					
	EPO	  	1915389	 	08/11/06	  	Hillman, et al	  	DPOLT
					
	France	  	1915389	 	06/08/11	  	Hillman, et al	  	DPOLT
					
	Germany	  	1915389	 	06/08/11	  	Hillman, et al	  	DPOLT
					
	Great Britain	  	1915389	 	06/08/11	  	Hillman, et al	  	DPOLT
					
	Hong Kong	  	1122721B	 	11/02/05	  	Hillman, et al	  	LPT3-04
		  	1915389	 	08/11/06	  	Hillman, et al	  	DPOLT
					
	Ireland	  	1915389	 	06/08/11	  	Hillman, et al	  	DPOLT
					
	Italy	  	1915389	 	06/08/11	  	Hillman, et al	  	DPOLT
					
	Mexico	  	280668	 	08/11/06	  	Hillman, et al	  	DPOLT
					
	Netherlands	  	1915389	 	06/08/11	  	Hillman, et al	  	DPOLT
					
	New Zealand	  	545730	 	08/10/04	  	Hillman	  	ProBiora3
		  	566546	 	08/11/06	  	Hillman, et al	  	DPOLT
					
	Spain	  	1915389	 	06/08/11	  	Hillman, et al	  	DPOLT
					
	Sweden	  	1915389	 	06/08/11	  	Hillman, et al	  	DPOLT
					
	Switzerland	  	1915389	 	06/08/11	  	Hillman, et al	  	DPOLT

 Pending Patent Applications 

 

									
	 *Country
	  	 Application No.
	 	 Filing Date
	  	 Inventor(s)
	  	 Title

	United States	  	13/017,214	 	01/31/11	  	Hillman	  	DIV of US patent no. 7,931,892
					
	United States	  	12/482,881	 	06/11/09	  	Hillman	  	Use of hydrogen peroxide bacteria for tooth whitening
					
	United States	  	11/265,414	 	11/02/05	  	Hillman, et al	  	Methods for regulating weight and size of animals

 Item B. Pending Patent Applications 

 

									
	 Country
	  	 Application No.
	 	 Filing Date
	  	 Inventor(s)
	  	 Title

					
	United States	  	13/212,574	 	08/18/11	  	Hillman, et al	  	Methods for treatment of lypomas and liposarcomas

									
	 Country
	  	 Application No.
	 	 Filing Date
	  	 Inventor(s)
	  	 Title

					
	United States	  	12/413,551	 	03/28/09	  	Hillman, et al	  	CIP of US Patent no. 7,521,529
					
	United States	  	13/302,006	 	11/22/11	  	Hillman	  	Use of bacteria to treat and prevent respiratory infections
					
	United States	  	61603693	 	02/27/12	  	Hillman, et al	  	Improved replacement therapy for dental caries
					
	 United States
	  	61603661	 	02/27/12	  	Hillman, et al	  	Variants of the lantibiotic
		  	MU1140 and other lantibiotics with improved pharmacological properties and structural features
					
	Australia	  	2009257440	 	06/11/09	  	Hillman	  	PB3 Whitening
		  	2006279749	 	08/11/06	  	Hillman, et al	  	DPOLT 1
		  	2010234987	 	03/25/10	  	Hillman, et al	  	DPOLT 2
					
	Canada	  	2727462	 	06/11/09	  	Hillman	  	PB3 Whitening
		  	2586239	 	11/02/05	  	Hillman, et al	  	LPT3-04
		  	2618066	 	08/11/06	  	Hillman, et al	  	DPOLT 1
		  	TBD	 	03/25/10	  	Hillman, et al	  	DPOLT 2
					
	China	  	200480029485	 	08/10/04	  	Hillman	  	ProBiora3
		  	201110291647.0	 	01/31/11	  	Hillman	  	ProBiora3 DIV
		  	200980131840.9	 	06/11/09	  	Hillman	  	PB3 Whitening
		  	200680037491.0	 	08/11/06	  	Hillman, et al	  	DPOLT 1
		  	TBA	 	03/25/10	  	Hillman, et al	  	DPOLT 2
					
	EPO	  	04780692.2	 	08/10/04	  	Hillman	  	ProBiora
		  	09763620.3	 	06/11/09	  	Hillman	  	PB3 Whitening
		  	10705505.5	 	02/18/10	  	Hillman	  	PB3 Lipomas
		  	05817085.3	 	11/02/05	  	Hillman, et al	  	ProBiora3
		  	10722821.5	 	03/25/10	  	Hillman, et al	  	DPOLT 2
					
	Hong Kong	  	08108087.9	 	08/11/06	  	Hillman, et al	  	DPOLT 1
					
	Japan	  	2006-53306	 	08/10/04	  	Hillman	  	ProBiora3
		  	2011-513687	 	06/11/09	  	Hillman	  	PB3 Whitening
		  	TBA	 	02/18/10	  	Hillman	  	PB3 Lipomas
		  	2007539325	 	11/02/05	  	Hillman, et al	  	LPT3-04
		  	2008-526260	 	08/11/06	  	Hillman, et al	  	DPOLT 1
		  	TBA	 	03/25/10	  	Hillman, et al	  	DPOLT 2
					
	Mexico	  	2010/013847	 	06/11/09	  	Hillman	  	PB3 Whitening
		  	2007005136	 	11/02/05	  	Hillman, et al	  	LPT3-04
		  	2011/009427	 	03/25/10	  	Hillman, et al	  	DPOLT 2
					
	New Zealand	  	590348	 	06/11/09	  	Hillman	  	PB3 Whitening
		  	594704	 	03/25/10	  	Hillman, et al	  	DPOLT 2
					
	PCT	  	09/047040	 	06/11/09	  	Hillman	  	PB3 Whitening
		  	2006/050432	 	11/02/05	  	Hillman	  	LPT3-04
		  	11/61784	 	11/22/11	  	Hillman	  	PB3 Resp. Infec.
					
	S. Korea	  	2006-7002806	 	08/10/04	  	Hillman	  	ProBiora3
		  	10-2011-7029892	 	06/11/09	  	Hillman	  	PB3 Whitening

 Item B. Patent Licenses 
  

											
	 Country or Territory
	  	 Licensor
	  	 Licensee
	  	 Effective Date
	  	 Expiration Date
	  	 Subject Matter

	United States	  	U. of FL	  	Oragenics	  	06/07/95	  	06/07/15	  	SMaRT Replacement therapy for dental caries
						
	United States	  	U of FL	  	Oragenics	  	06/10/97	  	06/10/17	  	MU1140 Novel antimicrobial polypeptide and methods of use
						
	United States	  	U of FL	  	Oragenics	  	07/27/99	  	07/27/19	  	MU1140 Novel antimicrobial polypeptide and methods of use

											
	 Country or Territory
	  	 Licensor
	  	 Licensee
	  	 Effective Date
	  	 Expiration Date
	  	 Subject Matter

						
	United States	  	U of FL	  	Oragenics	  	10/30/01	  	10/30/21	  	MU1140 Novel antimicrobial polypeptide and methods of use
						
	United States	  	U of FL	  	Oragenics	  	03/13/02	  	03/13/22	  	MU1140 Novel antimicrobial polypeptide and methods of use
						
	United States	  	U of FL	  	Oragenics	  	09/04/02	  	09/04/22	  	MU1140 Novel antimicrobial polypeptide and methods of use
						
	Australia	  	U of FL	  	Oragenics	  	06/09/98	  	06/09/18	  	MU1140
		  		  		  	06/07/96	  	6/07/15	  	SMaRT
						
	Austria	  	U of FL	  	Oragenics	  	06/07/96	  	06/07/15	  	SMaRT
						
	Belgium	  	U of FL	  	Oragenics	  	06/07/96	  	06/07/15	  	SMaRT
						
	Canada	  	U of FL	  	Oragenics	  	06/09/98	  	06/09/18	  	MU1140
		  		  		  	06/07/96	  	6/07/15	  	SMaRT
						
	Denmark	  	U of FL	  	Oragenics	  	06/07/96	  	06/07/15	  	SMaRT
						
	EPO	  	U of FL	  	Oragenics	  	06/09/98	  	06/09/18	  	MU1140
		  		  		  	06/07/96	  	06/07/15	  	SMaRT
						
	Finland	  	U of FL	  	Oragenics	  	06/07/96	  	06/07/15	  	SMaRT
						
	France	  	U of FL	  	Oragenics	  	06/09/98	  	06/09/18	  	MU1140
		  		  		  	06/07/96	  	06/07/15	  	SMaRT
						
	Germany	  	U of FL	  	Oragenics	  	06/09/98	  	06/09/18	  	MU1140
		  		  		  	06/07/96	  	06/07/15	  	SMaRT
						
	Great Britain	  	U of FL	  	Oragenics	  	06/09/98	  	06/09/18	  	MU1140
		  		  		  	06/07/96	  	06/07/15	  	SMaRT
						
	Greece	  	U of FL	  	Oragenics	  	06/09/98	  	06/09/18	  	MU1140
		  		  		  	06/07/96	  	06/07/15	  	SMaRT
						
	Hong Kong	  	U of FL	  	Oragenics	  	06/07/96	  	06/07/15	  	SMaRT
						
	Ireland	  	U of FL	  	Oragenics	  	06/09/98	  	06/09/18	  	MU1140
		  		  		  	06/07/96	  	06/07/15	  	SMaRT
						
	Italy	  	U of FL	  	Oragenics	  	06/09/98	  	06/09/18	  	MU1140
		  		  		  	06/07/96	  	06/07/15	  	SMaRT
						
	Japan	  	U of FL	  	Oragenics	  	06/09/98	  	06/09/98	  	MU1140
		  		  		  	06/07/96	  	06/07/15	  	SMaRT
						
	Luxemburg	  	U of FL	  	Oragenics	  	06/07/96	  	06/07/15	  	SMaRT
						
	Mexico	  	U of FL	  	Oragenics	  	06/07/96	  	06/07/15	  	SMaRT
						
	Monaco	  	U of FL	  	Oragenics	  	06/07/96	  	06/07/15	  	SMaRT
						
	Netherlands	  	U of FL	  	Oragenics	  	06/07/96	  	06/07/15	  	SMaRT
						
	New Zealand	  	U of FL	  	Oragenics	  	06/09/98	  	06/09/18	  	MU1140
		  		  		  	06/07/96	  	06/07/15	  	SMaRT
						
	Portugal	  	U of FL	  	Oragenics	  	06/07/96	  	06/07/15	  	SMaRT
						
	Russia	  	U of FL	  	Oragenics	  	06/07/96	  	06/07/15	  	SMaRT
						
	Spain	  	U of FL	  	Oragenics	  	06/09/98	  	06/09/18	  	MU1140
		  		  		  	06/07/96	  	06/07/15	  	SMaRT

											
	 Country or Territory
	  	 Licensor
	  	 Licensee
	  	 Effective Date
	  	 Expiration Date
	  	 Subject Matter

						
	Sweden	  	U of FL	  	Oragenics	  	06/09/98	  	06/09/18	  	MU1140
		  		  		  	06/07/96	  	06/07/15	  	SMaRT
						
	Switzerland	  	U of FL	  	Oragenics	  	06/07/96	  	06/07/15	  	SMaRT

 II. Trademarks 
 Item A. Registered Trademarks 
  

							
	 Country
	  	 Registration No.
	  	 Filing Date
	  	 Trademark

	United States	  	3747523	  	09/09/08	  	EVORAPLUS
		  	3883393	  	09/09/08	  	EVORAPRO
		  	3873950	  	09/09/08	  	EVORAKIDS
		  	3747524	  	09/09/08	  	PROBIORA3
		  	3806461	  	10/27/09	  	TEDDY’S PRIDE
	Australia	  	1434957	  	07/04/11	  	PROBIORA3
		  	1434960	  	07/04/11	  	TEDDY’S PRIDE
		  	1434956	  	07/04/11	  	EVORAPLUS
	Europe	  	8142424	  		  	PROBIORA3
	New Zealand	  	845099	  	07/04/11	  	EVORAPLUS
		  	845099	  	07/04/11	  	PROBIORA3
		  	845101	  	07/04/11	  	TEDDY’S PRIDE
	Taiwan	  	100028819	  	06/09/11	  	PROBIORA3
	Peru	  	465225	  	08/23/11	  	PROBIORA3

 Item B. Pending Trademark Applications 

 

							
	 Country
	  	 Serial No.
	  	 Filing Date
	  	 Trademark

	United States	  	TBD	  		  	EVORAPET
				
	 Country
	  	 Serial No.
	  	 Filing Date
	  	 Trademark

		  	85/466150	  	11/07/11	  	S. rattus JH145
		  	85/466139	  	11/07/11	  	S. uberis KJ2
		  	85/466154	  	11/07/11	  	S. oralis KJ3
	Argentina	  	3124889	  	12/09/11	  	EVORA
		  	3110268	  	12/09/11	  	PROBIORA3
	Brazil	  	840014023	  	02/08/12	  	EVORAPLUS
		  	Filed	  	02/08/12	  	PROBIORA3
	Canada	  	1562888	  	02/22/12	  	EVORAPET
	Chile	  	969767	  	09/13/11	  	PROBIORA3
		  	TBA	  	12/28/11	  	EVORAPLUS & Design
	Japan	  	2011-85965	  	11/29/11	  	EVORA
		  	2012-9311	  	02/21/12	  	PROBIORA3 & Design
		  	Filed	  		  	EVORAPET
	Mexico	  	1210545	  	09/09/11	  	EVORA
		  	12115905	  	09/29/11	  	PROBIORA3
	South Africa	  	2011/28125	  	11/04/11	  	TEDDY’S PRIDE
	S. Korea	  	40-2011-15952	  	03/29/11	  	PROBIORA3
		  	40-2011-15952	  	03/29/11	  	TEDDY’S PRIDE
	Taiwan	  	100028484	  	06/08/11	  	EVORAPLUS
		  	100028487	  	06/08/11	  	EVORAPLUS & Design
	Venezuela	  	TBA	  	03/05/12	  	EVORA
		  		  	2/30/11	  	PROBIORA3

 Item C. Unfiled Trademarks 

 

							
	 United States
	  	  	  	  	  	 Trademark

		  		  		  	MU1140
		  		  		  	DPOLT
		  		  		  	LPT3-04

 III. Copyrights. 
 None.Senior Secured Convertible Promissory Note

 Exhibit 10.4 
 THIS NOTE AND THE SHARES OF STOCK INTO WHICH IT IS CONVERTIBLE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933 OR STATE SECURITIES LAWS AND MAY NOT BE SOLD, TRANSFERRED, ASSIGNED, OFFERED,
PLEDGED OR OTHERWISE DISTRIBUTED FOR VALUE UNLESS THERE IS AN EFFECTIVE REGISTRATION STATEMENT UNDER SUCH ACT AND SUCH LAWS COVERING SUCH SECURITIES OR THE COMPANY RECEIVES AN OPINION OF COUNSEL ACCEPTABLE TO THE COMPANY STATING THAT SUCH SALE,
TRANSFER, ASSIGNMENT, OFFER, PLEDGE OR OTHER DISTRIBUTION FOR VALUE IS EXEMPT FROM THE REGISTRATION AND PROSPECTUS DELIVERY REQUIREMENTS OF SUCH ACT AND SUCH LAWS. 
 SENIOR SECURED CONVERTIBLE PROMISSORY NOTE 
  

			
	 	  	March 23, 2012
	$2,500,000.00	  	
		  	Tampa, Florida

 Oragenics, Inc., a Florida corporation (the “Company”), for value received,
hereby promises to pay to Koski Family Limited Partnership, a Texas limited partnership (the “Holder”), the principal sum of Two Million Five Hundred Thousand and no/100 Dollars ($2,500,000.00), or so much as has been
advanced hereunder as provided in that certain Loan Agreement (as amended, restated, modified or supplemented at any time or from time to time, the “Loan Agreement”) between the Company and Holder dated as of event date herewith,
and remains unpaid, plus interest as herein provided, in lawful money of the United States of America, on March 23, 2015 (the “Maturity Date”). This Note is subject to the following terms and conditions: 

9. INTEREST. This Note shall bear interest at a fixed rate of interest per annum of 5.00%. Interest payable pursuant to the terms
of this Note shall be based on the actual number of days elapsed over a year of 365 or 366 days, as applicable. 
 10.
REPAYMENT. The entire outstanding principal balance of this Note together with all accrued interest hereon as provided herein shall be due and payable in full on the Maturity Date. 

11. CONVERSION. Upon the closing of a Qualified Financing (as defined below) all principal and accrued but unpaid interest on this Note
shall automatically convert into shares of the same class and series of stock of the Company on the same terms and conditions, including per share price, as such shares are issued in one issue or a series of related issues (not including the value
of the converted Loan) in a private offering to “Accredited Investors” (the “Qualified Financing Securities”). For purposes herein, a “Qualified Financing” means the first transaction or series of
transactions pursuant to which the Company issues and sells shares of stock to Accredited Investors for aggregate gross proceeds to the Company of at least $5,000,000.00, excluding all proceeds from the incurrence of indebtedness that is converted
into such shares of stock, with the principal purpose of raising capital. If no Qualified Financing shall have been consummated before the Maturity Date, the Holder shall have the right, immediately upon written demand, to require repayment
of all unpaid principal and accrued interest on this Note. As promptly as practicable after the conversion of this Note as provided above, the Holder shall surrender this Note to the Company for cancellation, whereupon the Company shall issue and
deliver to the Holder, in the name of the Holder, evidence of the equity of the Company issuable upon the conversion of this Note. No fractional shares shall be issued upon conversion of this Note. If conversion of this Note would result in the
issuance of a fractional share, the amount payable under this Note that therefore cannot be applied to the purchase of the shares purchasable upon conversion shall be forgiven by the Holder without any further action on the part of the Holder or the
Company. 

 12. EVENT OF DEFAULT. This Note shall be in default upon the occurrence of an Event of
Default (as such term is defined in the Loan Agreement). 
 13. REMEDIES. If an Event of Default occurs and is not cured within
the applicable grace or curative period therefor, the Holder may declare the principal of this Note, together with any accrued and unpaid interest, if not already due, to be due and payable immediately, by written notice to the Company. Upon any
such declaration, such principal and interest will become due and payable immediately, anything contained in this Note to the contrary notwithstanding, and thereupon, the Holder shall be entitled to exercise all rights and remedies under this Note,
the Loan Agreement, the Security Agreement (as defined in the Loan Agreement), at law or in equity, including without limitation all of its rights and remedies as a secured party under the Florida Uniform Commercial Code. 

14. PREPAYMENT. This Note may be prepaid in whole or in part at any time without penalty or premium. 

15. TRANSFER. This Note may not be transferred or sold, or pledged, hypothecated or otherwise granted as security, by Holder. 

16. MISCELLANEOUS 
 8.1 GOVERNING LAW. This Note will be deemed to be a contract made under the laws of the State of Florida, and for all purposes will be construed in accordance with the laws of the State of Florida.

 8.2 BINDING EFFECT. This Note shall be binding upon, and inure to the benefit of, the Company and the Holder, and their
respective successors, and/or permitted assigns. 
 8.3 EXPENSES OF COLLECTION. In the event of any default by the Company in
its obligations hereunder, the Company shall reimburse the Holder on demand the amount of its costs and expenses in enforcing its rights hereunder, including reasonable attorneys fees. 

8.4 WAIVER OF JURY TRIAL. THE COMPANY AND HOLDER HEREBY KNOWINGLY, VOLUNTARILY AND INTENTIONALLY WAIVE ANY AND ALL RIGHTS THEY MAY
HAVE TO A TRIAL BY JURY IN RESPECT OF ANY LITIGATION (INCLUDING, BUT NOT LIMITED TO, ANY CLAIMS, CROSSCLAIMS OR THIRD-PARTY CLAIMS) ARISING OUT OF, UNDER OR IN CONNECTION WITH THIS NOTE. THE COMPANY HEREBY CERTIFIES THAT NO REPRESENTATIVE OR AGENT
OF HOLDER OR HOLDER’S COUNSEL HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT HOLDER WOULD NOT, IN THE EVENT OF SUCH LITIGATION, SEEK TO ENFORCE THIS WAIVER OF RIGHT TO JURY TRIAL PROVISION. 

 IN WITNESS WHEREOF, the Company has caused this Note to be duly executed as of the
day and year first set forth above. 
  

			
	ORAGENICS, INC.,
	a Florida corporation
		
	By:	 	 /s/ John N. Bonfiglio

	Name:	 	John N. Bonfiglio
	Title:	 	President and Chief Executive Officer

 THIS NOTE HAS BEEN BOTH EXECUTED AND DELIVERED OUTSIDE OF THE TERRITORIAL LIMITS OF THE STATE OF FLORIDA AND IS
THEREFORE NOT SUBJECT TO FLORIDA DOCUMENTARY STAMP TAX.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00201-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00201-of-00352.parquet"}]]